The price for Serono may go up even further now it looks like both GSK and Novartis might be bidding for them. There's nothing like being "piggy in the middle" to push the price up.
Look at Boots Healthcare International, for example. GSK lost in that one.
Shares of Geneva-based Serono have risen 28 percent since November on optimism about a sale. Novartis and Glaxo are both developing new oral multiple sclerosis drugs and are attracted by Rebif, which brings in half of Serono's sales. A buyer would also get the Gonal-F fertility treatment, experimental drugs for cancer and inflammatory illnesses and production capacity.
Insiders' view: do I hear more than $13 billion?
Source: Bloomberg
No comments:
Post a Comment